Tag: ASH Annual Meeting
Zilovertamab vedotin Demonstrates Encouraging Clinical Activity in B-Cell Cancers
A novel ROR1-targeted antibody-drug conjugate (ADC), zilovertamab vedotin, also known as MK-2140 or VLS-101, has demonstrated encouraging clinical efficacy, consistent pharmacokinetics, and a favorable...